The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib (LY3537982) as a monotherapy for the treatment of adult patients with advanced pancreatic cancer harboring a KRAS G12C mutation who have received at least one prior systemic therapy. The designation, announced by Eli Lilly and Company on August 3, 2026, marks a significant milestone in addressing a disease with few targeted options and historically poor outcomes.

Clinical Takeaway

✔ Olomorasib has received its second FDA Breakthrough Therapy designation, this time as monotherapy for previously treated KRAS G12C–mutant advanced pancreatic cancer — a setting with no currently approved targeted therapies.

✔ No FDA-approved therapies specifically targeting KRAS G12C-mutant pancreatic cancer currently exist, underscoring the urgent unmet need this designation aims to address.

✔ The designation is supported by preliminary data from the Phase 1/2 LOXO-RAS-20001 study (NCT04956640), which evaluated olomorasib in patients with KRAS G12C–mutant advanced solid tumors.

Drug Profile & Mechanism

  • Generic name: Olomorasib (LY3537982)
  • Drug class: Investigational, oral, next-generation KRAS G12C inhibitor
  • Mechanism: Specifically designed to bind and inhibit the KRAS G12C oncoprotein; engineered with pharmacokinetic properties that allow for high predicted target occupancy and high potency as monotherapy or in combination
  • Administration: Oral
  • Development stage: Investigational — not yet FDA approved

Disease Background & Target Population

  • Pancreatic cancer incidence: Approximately 60,000 new diagnoses per year in the United States, with an estimated 50,000 deaths annually
  • Prognosis: Metastatic pancreatic cancer carries a five-year survival rate of under 5%, making it one of the most lethal malignancies
  • KRAS mutation prevalence: KRAS mutations are present in approximately 90% of all pancreatic cancers; the specific KRAS G12C variant occurs in approximately 1%–2% of pancreatic cancer patients
  • Prognostic impact of KRAS G12C: Growing evidence suggests patients with KRAS G12C–mutant pancreatic cancer may experience poorer outcomes than those without the mutation, highlighting a critical unmet need
  • Current treatment gap: There are no FDA-approved therapies that specifically target the KRAS G12C mutation in pancreatic cancer
  • Designated patient population: Adult patients with advanced pancreatic cancer, a confirmed KRAS G12C mutation (by an FDA-approved test), and at least one prior line of systemic therapy

Supporting Study: LOXO-RAS-20001

  • Study name: LOXO-RAS-20001 (NCT04956640)
  • Design: Open-label, multicenter, Phase 1/2 trial
  • Objectives: Evaluate safety, tolerability, and preliminary efficacy of olomorasib in patients with KRAS G12C–mutant advanced solid tumors
  • Structure:
    • Phase 1a: Dose escalation of olomorasib monotherapy in KRAS G12C–mutant solid tumors
    • Phase 1b: Dose expansion and optimization evaluating olomorasib as monotherapy and in combination with other agents
  • Relevance to designation: Encouraging preliminary results from the pancreatic cancer cohort of this study formed the basis of the FDA’s Breakthrough Therapy designation decision

Regulatory Context & Broader Development Program

  • What Breakthrough Therapy designation means: The FDA grants this designation to expedite development and review of drugs for serious conditions when preliminary clinical evidence suggests substantial improvement over available therapies on a clinically significant endpoint; it provides more intensive FDA guidance during development and may accelerate the path to approval
  • Prior Breakthrough Therapy designation: Olomorasib was previously granted Breakthrough Therapy designation in combination with pembrolizumab (KEYTRUDA) for first-line locally advanced or metastatic NSCLC with a KRAS G12C mutation and PD-L1 expression ≥ 50%
  • Ongoing clinical development:
    • SUNRAY-01 (NCT06119581): Pivotal global study of olomorasib + pembrolizumab ± chemotherapy for first-line KRAS G12C–mutant advanced NSCLC
    • SUNRAY-02 (NCT06890598): Global study of olomorasib + standard-of-care immunotherapy in resected or unresectable KRAS G12C–mutant NSCLC

Key Clinical Implications

✔ Molecular testing is increasingly critical in pancreatic cancer. Although KRAS G12C occurs in only ~1%–2% of pancreatic tumors, identifying these patients through comprehensive molecular profiling is essential to direct them toward emerging targeted therapies.

✔ Olomorasib’s dual Breakthrough Therapy designations signal broad activity across KRAS G12C–driven tumor types. Clinicians managing NSCLC and pancreatic cancer should monitor ongoing trial readouts for both monotherapy and combination regimens.

✔ The second-line pancreatic cancer setting remains an area of profound unmet need. With no approved targeted options for KRAS G12C–mutant pancreatic cancer, enrollment of eligible patients into clinical trials should be considered whenever feasible.

✔ The Breakthrough Therapy designation does not constitute approval. Olomorasib remains investigational; full efficacy and safety data from ongoing trials will be required to support any future regulatory submission.

Bottom Line

The FDA’s Breakthrough Therapy designation for olomorasib monotherapy in previously treated KRAS G12C–mutant advanced pancreatic cancer represents a meaningful step forward in a disease long defined by therapeutic futility. With a five-year survival rate below 5% and no approved targeted options in this genomic subset, the designation reflects both the urgency of the unmet need and the promising early signal observed with this next-generation KRAS G12C inhibitor. As Lilly’s development program expands across tumor types and treatment settings, olomorasib is emerging as one of the most closely watched agents in the KRAS-targeted therapy landscape.

Sources